01 1Loba biotech GmbH
02 1Sentio BioSciences LLC
01 2Melarsomine Dihydrochloride
01 1Austria
02 1U.S.A
NDC Package Code : 62668-6281
Start Marketing Date : 2010-04-14
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 49405-001
Start Marketing Date : 2017-03-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1.5kg/1.5kg)
Marketing Category : BULK INGREDIENT
A Cymelarsan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cymelarsan, including repackagers and relabelers. The FDA regulates Cymelarsan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cymelarsan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cymelarsan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cymelarsan supplier is an individual or a company that provides Cymelarsan active pharmaceutical ingredient (API) or Cymelarsan finished formulations upon request. The Cymelarsan suppliers may include Cymelarsan API manufacturers, exporters, distributors and traders.
click here to find a list of Cymelarsan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cymelarsan as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cymelarsan API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cymelarsan as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cymelarsan and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cymelarsan NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cymelarsan suppliers with NDC on PharmaCompass.
We have 2 companies offering Cymelarsan
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
